{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:08:29Z","timestamp":1770509309394,"version":"3.49.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1097\/ico.0000000000000007","type":"journal-article","created":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T09:25:24Z","timestamp":1384507524000},"page":"60-64","source":"Crossref","is-referenced-by-count":18,"title":["Comparative Study of Ranibizumab and Bevacizumab on Corneal Neovascularization in Rabbits"],"prefix":"10.1097","volume":"33","author":[{"given":"Eun Kyoung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Joon","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Kun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-13-20210204","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/10454411950060030501","article-title":"The pathophysiology of angiogenesis.","volume":"6","author":"Polverini","year":"1995","journal-title":"Crit Rev Oral Biol Med"},{"key":"R2-13-20210204","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/ICO.0b013e31815cf67d","article-title":". Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).","volume":"27","author":"Kim","year":"2008","journal-title":"Cornea"},{"key":"R3-13-20210204","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00003226-198706040-00004","article-title":". Corneal neovascularization. Pathogenesis and inhibition.","volume":"6","author":"Epstein","year":"1987","journal-title":"Cornea"},{"key":"R4-13-20210204","first-page":"2485","article-title":"Loss and restoration of immune privilege in eyes with corneal neovascularization.","volume":"37","author":"Dana","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R5-13-20210204","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3341\/kjo.2010.24.4.230","article-title":"The effect of bevacizumab on corneal neovascularization in rabbits.","volume":"24","author":"Kim","year":"2010","journal-title":"Korean J Ophthalmol"},{"key":"R6-13-20210204","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","article-title":"Ocular neovascularization: an epidemiologic review.","volume":"43","author":"Lee","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"R7-13-20210204","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/0002-9394(68)90821-0","article-title":". Prevention of corneal vascularization.","volume":"66","author":"Ey","year":"1968","journal-title":"Am J Ophthalmol"},{"key":"R8-13-20210204","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00417-007-0542-4","article-title":". Inhibition of corneal angiogenesis by ascorbic acid in the rat model.","volume":"245","author":"Peyman","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R9-13-20210204","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/emboj\/19.7.1525","article-title":". Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis.","volume":"19","author":"Binetruy-Tournaire","year":"2000","journal-title":"EMBO J"},{"key":"R10-13-20210204","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-0420.2004.00312.x","article-title":"Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing.","volume":"82","author":"Gan","year":"2004","journal-title":"Acta Ophthalmol Scand"},{"key":"R11-13-20210204","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ajo.2006.10.004","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.","volume":"143","author":"Chen","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R12-13-20210204","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":". Ranibizumab versus verteporfin for neovascular age-related macular degeneration.","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"R13-13-20210204","first-page":"4593","article-title":". Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"R14-13-20210204","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":". Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"R15-13-20210204","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ajo.2006.06.066","article-title":". Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.","volume":"142","author":"Iliev","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R16-13-20210204","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.mehy.2006.06.063","article-title":"A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents.","volume":"68","author":"Hosseini","year":"2007","journal-title":"Med Hypotheses"},{"key":"R17-13-20210204","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","article-title":"The role of vascular endothelial growth factor in ocular health and disease.","volume":"25","author":"Adamis","year":"2005","journal-title":"Retina"},{"key":"R18-13-20210204","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":". Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R19-13-20210204","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/bjo.2006.107417","article-title":". Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier.","volume":"91","author":"Ambati","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R20-13-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2710.2007.00800.x","article-title":"Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.","volume":"32","author":"Kramer","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"R21-13-20210204","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00417-007-0568-7","article-title":". Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.","volume":"245","author":"Spitzer","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R22-13-20210204","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","article-title":". Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.","volume":"33","author":"Bahar","year":"2008","journal-title":"Curr Eye Res"},{"key":"R23-13-20210204","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1590\/S0001-37652007000300004","article-title":"The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea.","volume":"79","author":"Barros","year":"2007","journal-title":"An Acad Bras Cienc"},{"key":"R24-13-20210204","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.ico.0000611440.32234.8f","article-title":"Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis.","volume":"27","author":"Carrasco","year":"2008","journal-title":"Cornea"},{"key":"R25-13-20210204","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1167\/iovs.07-1175","article-title":". Interaction between bevacizumab and murine VEGF-A: a reassessment.","volume":"49","author":"Yu","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R26-13-20210204","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","article-title":". Safety profile of bevacizumab on cultured human corneal cells.","volume":"26","author":"Yoeruek","year":"2007","journal-title":"Cornea"},{"key":"R27-13-20210204","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1167\/iovs.08-1997","article-title":". Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.","volume":"50","author":"Chen","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000000007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:07:52Z","timestamp":1620954472000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201401000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000000007","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}